Telix Pharmaceuticals inks deal with Endocyte

Company News

by Anna Napoli

Pharmaceutical company, Telix Pharmaceuticals (ASX:TLX) has signed a contract with US biotech company Endocyte.

The deal will see Telix provide imaging technology for Endocytes phase 3 vision trial.

The trial is an international study of the treatment of patients with progressive prostate cancer.

Telix Pharmaceuticals is a biopharmaceutical company that is developing a portfolio of clinical-stage oncology products.

Shares in Telix (ASX:TLX) are trading 4.31 per cent higher to 60 cents.
  

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.